Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris Handed Another Chance On US Epoprostenol Challenge

US Federal Circuit Orders Viatris Veletri Case Back To District Court

Executive Summary

The US Court of Appeals for the Federal Circuit did not agree with the way a lower court adopted critical claim construction language in Viatris’ patent-litigation proceedings with Actelion over its Veletri injectable treatment for pulmonary arterial hypertension.

You may also be interested in...



Leaner Kabi Drives Higher Savings Goal For Fresenius, China ‘Soft’ In 2024

Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.

Unipharm Plavix Ruling May Change Game On Recouping Lost Generics Profits In Israel

In a much watched and controversial case that may have significant ramifications on the “chilling effects” of generics manufacturers in Israel being deterred from chasing after approvals in which an originator has deceitfully sought to ‘evergreen’ its branded intellectual property, the Israeli Supreme Court has once again come down on the side of the generics industry.

A $31bn Opportunity? Future Of Biosimilars Inches Closer With Samsung Keytruda Study

Samsung Bioepis is among a small pool of players heading to the clinic for a proposed biosimilar to Merck & Co’s PD-1 mega-blockbuster, as interest and investment rises ahead of patent expiry at the end of the decade.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel